Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients
- 30 June 2008
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 42 (5) , 345-349
- https://doi.org/10.1038/bmt.2008.170
Abstract
Mucosal damage to the intestines induced by myeloablative conditioning for allogeneic PBSC transplant (PBSCT) can be determined by the concentration of citrulline, which is a functional marker of small intestinal enterocytes. Low citrulline concentrations in blood coincide with and are a response to severe mucosal barrier injury. We treated 29 patients with high-dose melphalan 200 mg/m(2) (Mel-200) to prepare for an autologous PBSCT and collected plasma samples from each patient starting before the myeloablative regimen and three times per week thereafter until discharge. The baseline citrulline concentration was 27.6 mM+/-4.0 (mean+/-95% confidence interval; CI), and citrulline concentrations declined rapidly thereafter reaching a nadir averaging 6.7 mM+/-2.7, 12 days after starting Mel-200. Citrulline concentrations, only increased gradually and were still low (12 mM+/-4) at discharge. A total of 20 patients developed fever, which was associated with bacteraemia in 10 cases. Their mean citrulline concentrations were lower at 5.5 mM+/-1.5 than were those of patients without bacteraemia (10.2 mM+/-3.9). Importantly, neither the number of preceding neutropenic days nor the mean C-reactive protein (CRP) concentration at the onset of fever was different between these two groups. In conclusion, citrulline concentrations rapidly decline after Mel-200 reflecting intestinal mucosal barrier injury. Low citrulline, rather than the duration of neutropenia, is associated with bacteraemia indicating the importance of an intact mucosal barrier in neutropenic patients.Keywords
This publication has 30 references indexed in Scilit:
- Prospective Oral Mucositis Audit: Oral Mucositis in Patients Receiving High-Dose Melphalan or BEAM Conditioning Chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory GroupJournal of Clinical Oncology, 2008
- Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipientsBone Marrow Transplantation, 2005
- Management of the febrile neutropenic cancer patient: lessons from 40 years of studyClinical Microbiology & Infection, 2005
- Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapyBone Marrow Transplantation, 2004
- Preventing microbial translocation in haematological malignancyBritish Journal of Haematology, 2004
- Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescueBritish Journal of Haematology, 2000
- The impact of mucositis on ?-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignanciesCancer, 1998
- o-phthaldialdehyde precolumn derivatization and reversed-phase high-performance liquid chromatography of polypeptide hydrolysates and physiological fluidsJournal of Chromatography A, 1983
- Report of the committee on the genetic constitution of autosomes other than chromosomes 1, 2, and 6Cytogenetic and Genome Research, 1976
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaAnnals of Internal Medicine, 1966